Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company have announced the commercial availability of POSLUMA® (flotufolastat F 18) in the United States. POSLUMA is an optimized, high-affinity radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It was approved by the U.S. Food and Drug Administration on May 25, 2023. By the end of June 2023, commercial production across the country will be underway at the 31 PETNET radiopharmacies Blue Earth Diagnostics included in its New Drug Application for POSLUMA.
Blue Earth Diagnostics and PETNET Solutions Inc are proud to provide broad access to POSLUMA, as well as a wide range of other novel PET biomarkers that facilitate precision medicine for healthcare providers across the country. The companies share a passion for PET molecular imaging and providing imaging tools to help inform patient care.
Keywords: Blue Earth Diagnostics, PETNET Solutions Inc, PSMA-targeted PET imaging agent, prostate cancer, radioph